The invention discloses an anti-apoptosis Mcl-1 protein inhibitor, and applications thereof, and belongs to the field of medical technology. The anti-apoptosis Mcl-1 protein inhibitor is a 6,7-dihydroxycoumarin derivative, and the general structure is represented by formula (I), wherein R1 and R2 are used for representing H or (C1-C6) alkyl groups, R3 is used for representing H or CH2NR5R6, NR5R6 is one randomly selected from dimethylamine, diethylamine, dipropyl amine, diisopropylamine, pyrrolidine, piperidine, morpholine, piperazine, or structure derivatives thereof, R4 is used for representing one randomly selected from H, (C1-C6) alkyl groups, CF3, OH-(C1-C6) alkyl groups, and halogenated-(C1-C6) alkyl groups. The anti-apoptosis Mcl-1 protein inhibitor is used for inducing cell apoptosis via competitive binding and antagonism with Mcl-1 protein, killing tumor cells, and can be taken as an anticancer medicine. The anti-apoptosis Mcl-1 protein inhibitor is low in molecular weight, excellent in membrane permeable performance, and high in safety, and possessing a promising prospect in development of medicines.